首页> 外文期刊>Urology >Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein.
【24h】

Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein.

机译:局限在肾静脉的病理性T3bNxM0肾细胞癌的保肾手术的单一机构经验。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess our institution's experience with the management of pathologic stage T3bNxM0 renal cell carcinoma with tumor thrombus confined to the renal vein treated with nephron-sparing surgery (NSS). METHODS: Of the 492 patients who have undergone NSS at Columbia University from 1998 to 2009, 8 patients were found to have stage T3bNxM0 renal cell carcinoma (RCC) on final pathology. Records were reviewed for indication for NSS, imaging studies, perioperative management, surgical details, pathology, and both functional and disease-specific outcomes. Postoperative renal function was estimated by most recent glomerular filtration rate using Modification of Diet in Renal Disease formula. Recurrence of RCC was monitored using serial axial imaging. RESULTS: The 8 patients were presumed to be clinical stage T1aN0M0 RCC before surgery; however, tumor thrombus was identified in the renal vein intraoperatively and on final pathology in 4, and 4 cases, respectively, corresponding to stage T3bNxM0 RCC by current American Joint Committee on Cancer-Tumor-Necrosis-Metastasis 2002 criteria. After a median follow-up of 19.8 months, the patients experienced a mean decrease in estimated glomerular filtration rate of 27.1%. One patient developed new-onset renal failure, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m(2). Clean surgical margins were obtained in 7 patients. Carcinoma was identified at the parenchymal margin in 1 patient. No patients have evidence of recurrence of RCC by serial axial imaging. CONCLUSIONS: NSS does not seem to have had a negative impact on a small series of patients with pathologic stage T3bNxM0 RCC limited to the renal vein and may be a feasible option when the clinical situation indicates a need for preservation of renal function.
机译:目的:评估我们机构在病理性T3bNxM0型肾细胞癌的治疗中的经验,该肿瘤的血栓仅限于保肾术(NSS)治疗的肾静脉。方法:在1998年至2009年哥伦比亚大学(Columbia University)接受过NSS的492例患者中,有8例的最终病理结果为T3bNxM0期肾细胞癌(RCC)。审查记录,以用于NSS,影像学研究,围手术期管理,手术细节,病理以及功能和疾病特异性结局的指征。肾功能的最新估计是根据最近的肾小球滤过率通过修改肾脏疾病配方中的饮食来估计的。使用串行轴向成像监测RCC的复发。结果:这8例患者被认为是术前T1aN0M0 RCC临床分期。然而,根据现行的2002年美国癌症,肿瘤,坏死,转移联合委员会的标准,分别在4例和4例患者的术中和最终病理学中在肾静脉中发现了肿瘤血栓。中位随访19.8个月后,患者的肾小球滤过率估计平均下降了27.1%。一名患者出现新发性肾衰竭,定义为肾小球滤过率估计低于30 mL / min / 1.73 m(2)。 7例患者获得了干净的手术切缘。在1例患者的实质边缘发现了癌。没有患者通过串行轴向影像学检查发现RCC复发。结论:NSS似乎对少数病理期T3bNxM0 RCC限于肾静脉的患者没有负面影响,当临床情况表明需要保留肾功能时,NSS可能是可行的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号